The German company STRATEC referred projections that the in vitro diagnostics (IVD) market will continue to generate very healthy and sustainable growth rates. Currently, this
Johnson & Johnson posted a 6.5% year-over-year increase in sales of its Stelara (ustekinumab) treatment for pediatric patients with juvenile psoriatic arthritis in 2022, to
The German company STRATEC referred projections that the in vitro diagnostics (IVD) market will continue to generate very healthy and sustainable growth rates. Currently, this
Johnson & Johnson posted a 6.5% year-over-year increase in sales of its Stelara (ustekinumab) treatment for pediatric patients with juvenile psoriatic arthritis in 2022, to
Redacción: 7224059128
info@opportimes.com
